Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
about
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentPhase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.Evaluation of dosing strategy for pembrolizumab for oncology indications.Pembrolizumab for the treatment of non-small cell lung cancer.Gastric adenocarcinoma.Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer.A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed.Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity.Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
P2860
Q28076294-349672AC-0588-4FA6-8001-55614C40159BQ36356089-46EFFB46-3B03-4381-82FA-2E6BEDE8186EQ37688658-1F159E04-7005-4911-8651-ED7FD9CC1E8BQ38640845-63797441-3C70-4CA8-B3D3-93E39EBF8431Q38779793-987CC7CC-EDE6-42D3-AF65-4CED656A3FE1Q39198286-9B083E8F-5891-46BE-A7A9-3396227A1DBDQ39343374-EA060A8F-C584-4F99-881E-BA0079400456Q40346982-3170FF78-DE6B-4756-AF63-550085347939Q45952214-F3E00700-AFA7-4433-95E7-4394C1CB2B1FQ47101155-7709A428-3089-465A-8092-FD5AE2C2DF9BQ47107969-7DE8D5D5-B208-42A5-B93B-9BD1AEFE4314Q47615991-2267A68D-DF64-425F-A404-2C81544F5F77Q47969034-E74FEE6F-8F26-4CDC-A0BB-D2C309E6AF7EQ49333794-2EF06038-1E83-4407-97D5-961B6B9E9061Q50606627-4E64691D-D209-4BB1-88B2-F8207C01C06CQ51161116-F9BB1E44-0D77-47EB-B943-F9E4AB9C847AQ55008531-8322C52D-73B5-4DD3-978A-A8FBB2081558Q57214474-DC8C801E-E9D9-4505-877A-CB42074B3A9A
P2860
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Systematic evaluation of pembr ...... ed non-small-cell lung cancer.
@en
Systematic evaluation of pembr ...... ed non-small-cell lung cancer.
@nl
type
label
Systematic evaluation of pembr ...... ed non-small-cell lung cancer.
@en
Systematic evaluation of pembr ...... ed non-small-cell lung cancer.
@nl
prefLabel
Systematic evaluation of pembr ...... ed non-small-cell lung cancer.
@en
Systematic evaluation of pembr ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Systematic evaluation of pembr ...... ced non-small-cell lung cancer
@en
P2093
A G Kondic
D C Turner
D P De Alwis
G M Lubiniecki
H-T Arkenau
P2860
P304
P356
10.1093/ANNONC/MDW174
P577
2016-04-26T00:00:00Z